Is there a future for biologics in the management of chronic rhinosinusitis?
Authors:
- 22 April 2016
- journal article
- review article
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 6 (9) , 935-942
Abstract
Background: Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory condition of the sinonasal mucosa consisting of poorly defined subtypes and characterized by variable clinical manifestations, responses to therapy, and underlying pathophysiologies. In the related disorder of asthma, progress has been made in defining disease subtypes on both clinical and pathophysiologic levels, facilitating the development of targeted biologic pharmacotherapy. The potential role of these drugs for the management of CRS will be reviewed. The objective of this work is to highlight the emerging therapeutic targets in CRS in light of evolving treatment options for asthma and enhanced understandings of the clinical manifestations and pathophysiology of CRS.Methods: This article is a review of recent studies regarding current and future advances in biomarker‐directed therapies in the medical treatment of CRS.Results: Various biologic therapies used in the management of asthma have demonstrated clinical promise for CRS, particularly within the CRS with nasal polyposis (CRSwNP) phenotype. Several randomized, double‐blind, placebo‐controlled studies increasingly support the targeting of immunoglobulin E (IgE) and interleukin (IL)‐5 pathways to improve outcome measures in CRSwNP patients. The IL‐4/IL‐13 pathway and other type 2 inflammatory pathways have also shown potential as targets for CRSwNP, but all pathways require further investigation.Conclusion: Recalcitrant CRS in the United States and Europe is most commonly associated with nasal polyposis and a type 2 cytokine skewing in the tissue, resulting in tissue infiltration of eosinophils, mast cells, and basophils. Targeting biomarkers of the associated type 2 pathways may be a practical treatment option for recalcitrant CRSwNP in the future.Keywords
Funding Information
- Center for Clinical and Translational Sciences
- National Institutes of Health Clinical and Translational Award (UL1 TR000371, KL2 TR000370)
- National Center for Advancing Translational Science
This publication has 80 references indexed in Scilit:
- Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitisJournal of Allergy and Clinical Immunology, 2013
- Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroidsJournal of Allergy and Clinical Immunology, 2013
- Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytesBlood, 2012
- Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthmaExpert Opinion on Biological Therapy, 2011
- What targeting eosinophils has taught us about their role in diseasesJournal of Allergy and Clinical Immunology, 2010
- Treatment-Recalcitrant Chronic Rhinosinusitis with Polyps is Associated with Altered Epithelial Cell Expression of Interleukin-33American Journal of Rhinology & Allergy, 2010
- Perspectives on the etiology of chronic rhinosinusitisCurrent Opinion in Otolaryngology & Head and Neck Surgery, 2010
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Resolution of Allergic Inflammation and Airway Hyperreactivity Is Dependent upon Disruption of the T1/ST2–IL-33 PathwayAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Perspectives on the Etiology of Chronic Rhinosinusitis: An Immune Barrier HypothesisAmerican Journal of Rhinology, 2008